首项比较R-CHOP与标准CHOP治疗弥漫大B细胞性淋巴瘤的LNH-98.5随机临床研究的长期随访结果：Groupe d'Etudes des Lymphomes de l'Adulte的研究

摘自：blood, 23 september 2010, vol. 116, no. 12, pp. 2040-2045.
中国肿瘤化疗   赵利平 翻译武汉协和医院肿瘤中心刘红利

我们在此报道中位随访10年的lnh-98.5研究结果。这个研究比较了r-chop与chop方案治疗年龄在60-80岁的399例弥漫大b细胞性淋巴瘤的疗效。2009年所有存活者的临床事件信息都已更新（除外3名患者）。r-chop组的生存终点得到了改善：10年的无进展生存率（pfs）为36.5%，总生存率（os）为43.5%；chop组的10年pfs只有20% ，os为27.6%。两组的由于其他疾病、第二肿瘤、后期复发导致的死亡率相同。出现在5年之后的复发占所有进展的7%。10年分析的结果证实了chop方案加美罗华的疗效与可接受的毒副反应。我们的研究结果强调需要把年长患者当作年轻患者对待，使用根治性的化疗方案去治疗。

long-term outcome of patients in the lnh-98.5 trial, the first randomized study comparing rituximab-chop to standard chop chemotherapy in dlbcl patients: a study by the groupe d'etudes des lymphomes de l'adulte

blood, 23 september 2010, vol. 116, no. 12, pp. 2040-2045.
prepublished online as a blood first edition paper on june 14, 2010; doi 10.1182/blood-2010-03-276246.

we report the outcome of patients included in the lnh-98.5 study, which compared cyclophosphamide, doxorubicin, vincristine, and prednisone (chop) to rituximab plus chop (r-chop) therapy in 399 patients with diffuse large b-cell lymphoma (dlbcl) aged 60 to 80 years, with a median follow-up time of 10 years. clinical event information was updated in all living patients (with the exception of 3 patients) in 2009. survival end points were improved in patients treated with r-chop: the 10-year progression-free survival was 36.5%, compared with 20% with chop alone, and the 10-year overall survival was 43.5% compared with 27.6%. the same risk of death due to other diseases, secondary cancers, and late relapses was observed in both study arms. relapses occurring after 5 years represented 7% of all disease progressions. the results from the 10-year analysis confirm the benefits and tolerability of the addition of rituximab to chop. our findings underscore the need to treat elderly patients as young patients, with the use of curative chemotherapy.